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Purpose of the study
To determine groups in HIV living people cohort in the
aspect of further HAART.
Methods
The data on 2271 patients was investigated in a cross-sec-
tional study. All patients at the moment of survey had no
attributes of clinical progression of disease and did not
receive HAART. Clinical exam and blood sampling was
performed, in blood specimens HIV virus load (PCR
m2000rt Abbott Biosystems analyzer, RealTime HIV-1
sets) and CD3+CD4+ and CD3+CD4- phenotypes of
T-lymphocytes were analyzed (flow cytometer BD FACS-
Count, sets of antibodies TriTEST CD3/CD4/CD45). For
363 patients additionally CD3+CD8+ and CD3+CD4-
CD8- (double negative) phenotypes of T-lymphocytes
were determined. Duration of HIV infection and the age
of the patient was also included into analysis. Received
data was processed statistically by means of SPSS software.
Summary of results
Factor analysis with the principle component method
revealed two major factors gathering 54% of the total
variance. The first factor included CD4+ and CD3+CD4-
T-lymphocyte counts with reverse influence of the viral
load. The second factor included CD3+CD4- counts con-
cordant with the viral load. Hierarchical cluster analysis
by Ward method was performed in the space of these
two factors and revealed 3 groups. Figure 1
The First Group had relatively small duration of disease
(about 3 years), well preserved CD4 counts (650 cells/
mm
3), CD3+CD8+, CD3+CD4-CD8- T-lymphocytes on
the average level characteristic for the HIV-living cohort.
The group was designated as temporary no progressive.
T h eS e c o n dG r o u ph a ds i g n i f i c a n td u r a t i o no fd i s e a s e
(5 years), almost intact CD4 counts, 4,1 time increase in
CD3+CD8+ T-lymphocytes and 10,3 increase of CD3
+CD4-CD8- counts in comparison with healthy controls.
This was permanent no progressive group. The Third
Group had also significant duration of disease (6 years),
different (from moderate to severe) depletion of all
detected subpopulations of T-cells as well as the highest
viral load. This was the progressive group, the members
of which had indications to HAART (27% of the popula-
tion). Table 1
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Figure 1 Bland-Altman plots comparing Framingham, Rama-EGAT,
and D:A:D risk scores
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1. Evaluation of no progressive status (temporary or per-
manent) as well as diagnostics of the progressive state
outlines indications to antiretroviral treatment. 2. Evalu-
ated internal groups support approach to start HAART
after CD4 cell counts are less than 500/mm
3 and the
depletion level of 350 CD4 cells/mm
3 lies in the middle
scope of progressive group.
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Table 1
Group
Number
Group Title CD3+ (cells/
mm
3)
CD4 +(cells/
mm
3)
CD8 +(cells/
mm
3)
CD3+CD4-CD8-
(cells/mm
3)
Viral Load (log 10
copies/ml)
Age
(years)
Disease Duration
(years)
1 Temporary No
Progressors
2321 654 1105 411 3,42 27,76 2,80
2 Permanently No
Progressors
3575 735 2243 658 4,00 36,06 4,76
3 Progressors 1771 366 969 268 4,50 32,64 6,17
4 HIV Infected Total 2363 589 1195 394 3,80 30,34 4,01
5 Healthy Controls 1554 944 545 64 - 28,62 -
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